RxDoctor Payments Data

Paulos Yohannes, MD

Urology · Naples, FLNPI 1043299985

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (46.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 63.4% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2022 at $4,427 and has fallen 55.0% since, to $1,992 in 2025.

$9,071in general payments, 2019–2025

Across 163 payments — averaging $55.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • Axonics, Inc.$478
  • Johnson & Johnson$367
  • Astellas Pharma US Inc$262
  • Blue Earth Diagnostics$211
  • AbbVie$196
  • plus $2K from 37 others

What the payments were for

  • Travel & lodging$1,47316%
  • Food & beverage$3,36337%
  • Education$4,23547%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,071 in reported general payments places this provider in the 75th percentile of 935 urology providers in Florida.

See all urology providers in Florida →

Medicare billing

Part B allowed, 2024
$1,205,422
Medicare patients
1,008
Services billed
11,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide11$160,807
GemtesaVibegron182$137,398
MyrbetriqMirabegron73$50,368
Potassium Citrate ErPotassium Citrate151$18,923
Testosterone32$6,555
Silodosin67$5,863
Tamsulosin Hcl429$4,876
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst71$2,452
Finasteride175$2,107
Methenamine Hippurate23$1,327
NitrofurantoinNitrofurantoin Macrocrystal34$1,319
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim115$1,100
Ciprofloxacin Hcl149$1,082
Solifenacin Succinate22$814
Dutasteride24$750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$262$211,17584 claims
Sumitomo Pharma America, Inc.Gemtesa$38$137,398182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 urology providers in Florida.

Other urology in Naples

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →